These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 27499539)

  • 1. Characterization of asthma endotypes: implications for therapy.
    Stokes JR; Casale TB
    Ann Allergy Asthma Immunol; 2016 Aug; 117(2):121-5. PubMed ID: 27499539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic and New Therapies in Asthma.
    Tabatabaian F; Ledford DK; Casale TB
    Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma.
    Bagnasco D; Ferrando M; Varricchi G; Passalacqua G; Canonica GW
    Int Arch Allergy Immunol; 2016; 170(2):122-31. PubMed ID: 27637004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Biologics in Severe Asthma.
    Pavord ID; Hilvering B; Shrimanker R
    Immunol Allergy Clin North Am; 2016 Aug; 36(3):609-23. PubMed ID: 27401629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of biologics in asthma endotypes.
    Wangberg H; Woessner K
    Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.
    Fajt ML; Wenzel SE
    J Allergy Clin Immunol; 2015 Feb; 135(2):299-310; quiz 311. PubMed ID: 25662302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
    Godar M; Blanchetot C; de Haard H; Lambrecht BN; Brusselle G
    MAbs; 2018 Jan; 10(1):34-45. PubMed ID: 29035619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe asthma: what is new in the new millennium.
    Ntontsi P; Samitas K; Zervas E; Gaga M
    Curr Opin Allergy Clin Immunol; 2020 Apr; 20(2):202-207. PubMed ID: 32004177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased serum IL-17A and Th2 cytokine levels in patients with severe uncontrolled asthma.
    Hasegawa T; Uga H; Mori A; Kurata H
    Eur Cytokine Netw; 2017 Mar; 28(1):8-18. PubMed ID: 28840844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
    Parulekar AD; Kao CC; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.
    Chung KF
    J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated levels of circulating CD4(+) CRTh2(+) T cells characterize severe asthma.
    Palikhe NS; Laratta C; Nahirney D; Vethanayagam D; Bhutani M; Vliagoftis H; Cameron L
    Clin Exp Allergy; 2016 Jun; 46(6):825-36. PubMed ID: 27079298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypes/endotypes-driven treatment in asthma.
    Braido F; Tiotiu A; Kowal K; Mihaicuta S; Novakova P; Oguzulgen IK
    Curr Opin Allergy Clin Immunol; 2018 Jun; 18(3):184-189. PubMed ID: 29601354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different endotypes and phenotypes drive the heterogeneity in severe asthma.
    McDowell PJ; Heaney LG
    Allergy; 2020 Feb; 75(2):302-310. PubMed ID: 31267562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T2-low asthma: current approach to diagnosis and therapy.
    Samitas K; Zervas E; Gaga M
    Curr Opin Pulm Med; 2017 Jan; 23(1):48-55. PubMed ID: 27798418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications.
    Robinson D; Humbert M; Buhl R; Cruz AA; Inoue H; Korom S; Hanania NA; Nair P
    Clin Exp Allergy; 2017 Feb; 47(2):161-175. PubMed ID: 28036144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient stratification and the unmet need in asthma.
    Swedin L; Saarne T; Rehnberg M; Glader P; Niedzielska M; Johansson G; Hazon P; Catley MC
    Pharmacol Ther; 2017 Jan; 169():13-34. PubMed ID: 27373855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic Therapy and Novel Molecular Targets of Severe Asthma.
    Pepper AN; Renz H; Casale TB; Garn H
    J Allergy Clin Immunol Pract; 2017; 5(4):909-916. PubMed ID: 28689841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics and biomarkers for asthma, urticaria, and nasal polyposis.
    Casale TB
    J Allergy Clin Immunol; 2017 May; 139(5):1411-1421. PubMed ID: 28477720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?
    De Ferrari L; Chiappori A; Bagnasco D; Riccio AM; Passalacqua G; Canonica GW
    Expert Rev Respir Med; 2016; 10(1):29-38. PubMed ID: 26566089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.